Kura Oncology, Inc.
NASDAQ:KURABiotechnology
+$0.07 today
- Market cap
- $674.39M
- Beta
- 0.36
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.32
Volume 2.46M
Average 1.66M
KURA Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Kura Oncology, Inc.NASDAQ: KURA
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $18.27M rose 29.5% year over year, ahead of the +5.4% change in trailing-twelve-month revenue. Sequentially, it rose 5.4% from the prior quarter.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 11 analysts of $93.11M (+38.0%) for the fiscal year ending Dec 2026, a step up from the +25.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $18.27M+5.4% QoQ
- Last fiscal yearDec 2025
- $67.48M+25.2% YoY
- LTMMar 2026
- $71.64M+5.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +29.5% | +31.9% | +2.4 pp |
| 1 year | +25.2% | +38.0% | +12.7 pp |
| 3-year CAGR | — | +60.0% | — |
| 5-year CAGR | +66.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 67.48M USD
- Year-over-year change
- +25.2%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 67.48M | +25.2% |
| FY2024 | 2024-12-31 | 53.88M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Revenue vs competitors
How KURA compares with its peers on the latest reported figures
- KURA's LTM Mar 2026 revenue of $71.64M is the 5th highest of the 11 companies compared; the peer median is $25.06M.
- Its year-over-year change of +5.4% is the 5th highest of 7, against a peer median of +221.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Aug 2026 | $701.94M | +738.8% | +29.5% | |
| LTM Jun 2025 | $602.2M | -1.4% | +8.9% | |
| LTM Mar 2026 | $299.77M | +47.6% | +34.8% | |
| LTM Mar 2026 | $217.17M | +396.7% | — | |
| LTM Mar 2026 | $71.64M | +5.4% | — | |
| LTM Mar 2026 | $49.59M | +395.8% | +128.4% | |
| LTM Mar 2026 | $525K | -10.7% | +15.4% | |
| LTM Sep 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $0 | — | — |
| Peer median (excluding KURA) | $25.06M | +221.7% | +29.5% | |
Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 53.88M | 67.48M |
| Cost of Revenue | 0 | 0 | 849K | 0 | 57K |
| Gross Profit | 0 | 0 | (849K) | 53.88M | 67.43M |
| Gross Margin | — | — | — | 100.0% | 99.9% |
| Research & Development | 84.72M | 92.81M | 115.24M | 169.97M | 251.07M |
| Selling, General & Admin | 46.54M | 47.05M | 50.57M | 77.11M | 119.98M |
| Operating Expenses | 131.26M | 139.87M | 164.96M | 247.08M | 371.06M |
| Depreciation & Amortization | 558K | 759K | 849K | 848K | 1.03M |
| EBITDA | (129.49M) | (134.85M) | (150.23M) | (169.5M) | (275.83M) |
| EBITDA Margin | — | — | — | -314.6% | -408.7% |
| Operating Income | (131.26M) | (139.87M) | (165.8M) | (193.2M) | (303.63M) |
| Operating Margin | — | — | — | -358.5% | -449.9% |
| Interest Income | 1.21M | 4.25M | 14.72M | 22.85M | 26.77M |
| Interest Expense | 414K | 229K | 1.55M | 1.62M | 1.51M |
| Other Income / Expenses | 792K | 4.03M | 13.17M | 21.23M | 25.26M |
| Income Before Tax | (130.47M) | (135.84M) | (152.63M) | (171.97M) | (278.37M) |
| Pre-Tax Margin | — | — | — | -319.1% | -412.5% |
| Income Tax Expense | 0 | 0 | 0 | 2.02M | 297K |
| Net Income | (130.47M) | (135.84M) | (152.63M) | (173.98M) | (278.67M) |
| Net Margin | — | — | — | -322.9% | -412.9% |
| EPS (Basic) | (1.97) | (2.03) | (2.08) | (2.02) | (3.18) |
| EPS (Diluted) | (1.97) | (2.03) | (2.08) | (2.02) | (3.18) |
| Weighted Avg Shares | 66.35M | 66.99M | 73.23M | 86.16M | 87.68M |
| Weighted Avg Shares (Diluted) | 66.35M | 66.99M | 73.23M | 86.16M | 87.68M |
Kura Oncology, Inc.
NASDAQ:KURA
Intrinsic Alpha fair value
Locked
Current Price
$7.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.